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3D Microtissue Formation of Undifferentiated
Bone Marrow Mesenchymal Stem Cells Leads
to Elevated Apoptosis
Jens M. Kelm, Ph.D.,1,2 Martin Breitbach, Ph.D.,3,* Gregor Fischer, D.V.M.,4,* Bernhard Odermatt, M.D.,5
Irina Agarkova, Ph.D.,1 Bernd K. Fleischmann, M.D.,3 and Simon P. Hoerstrup, M.D., Ph.D.1,2
Current implantation formats to deliver bone marrow-derived mesenchymal stem cells (MSCs) to the site of
myocardial injury resulted only in limited cell retention and integration. As an alternative concept to single cell
transplantation, we investigated the fate of cell tracker-labeled syngenic rat MSC microtissue implants, injected
into the scar area in a chronic rat myocardial infarction model. Analysis of the explants after 2 and 7 days
revealed substantial amounts of the cell tracker within the infarct region. However, the signal was associated
with the extracellular matrix rather than with viable implanted cells. Following these results, we systematically
evaluated the behavior of MSCs derived from mouse, rat, and human origin in the microtissue format in vitro.
We found that MSC-composed microtissues of all three species displayed highly elevated levels of apoptotic
activity and cell death. This effect could be attenuated by initiating osteogenic differentiation during the tissue
formation process. We conclude that MSCs used for tissue regeneration undergo apoptosis in their new envi-
ronment unless they get appropriate signals for differentiation that permit sustained survival. These findings
may explain the limited cellular regeneration potential in current MSC-based clinical trials and may change
therapeutic strategies away from pure, unmodulated cell delivery concepts.
Introduction
Bone marrow stromal cells (MSCs), also termed mes-enchymal stem or progenitor cells, are an adhesive cel-
lular fraction of the marrow with a fibroblastic phenotype in
cell culture.1 Due to a current lack of distinctive markers for
MSCs, the overall understanding of their function and phe-
notype in their physiological environment is limited and
based predominantly on in vitro data and in vivo transplan-
tation studies of labeled or genetically modified MSCs.2 Ever
since Pereira and coworkers demonstrated the contribution
of MSCs in regenerative tissue processes in irradiated mice,3
this cell source has gained increasing attention particularly
with regard to their applications in regenerative medicine.
They fulfill several characteristics such as self renewal, im-
munomodulation,4 and in vitro and in vivo differentiation
capacity, which makes them highly attractive for cell thera-
py.5 The fact that these cells can be harvested, enriched
in vitro, and used in an autologous fashion is particularly
appealing for therapeutic purposes. However, to date most
cell-based therapeutic approaches using systemic or local
delivery routes resulted only in modest integration into in-
jured tissue and consequently only marginal functional im-
provements have been reported.6,7 Moreover, the therapeutic
mechanisms of MSCs have remained elusive so far, since the
concept of transdifferentiation to, for example, the cardiac
lineage could not be clearly proven.8 The tissue repairing
mechanisms of MSCs are highly debated,9 but the most
broadly accepted hypothesis is based on paracrine effects
triggered by specific factors such as vascular endothelial
growth factor (VEGF), fibroblast growth factor-2 (FGF-2), or
hepatocyte growth factor (HGF).10,11 The importance of un-
derstanding the parameters, cytokines, and growth factors
directing the fate of MSCs in vitro and even more importantly
for their therapeutic use under physiological conditions
in vivo is highlighted by recent findings, displaying osteo-
genic MSC differentiation and calcification in the infarcted
scar tissue in mice.12,13 Nevertheless, the survival and
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temporal persistence after local delivery into injured tissue is
a key prerequisite for a therapeutic benefit. A recent study by
Mu¨ller-Ehmsen and coworkers demonstrated that 34%–80%
of the cells are detected immediately after cell injection, but
only 0.3%–3.5% could be identified after 6 weeks.14 Even
MSCs immortalized with the human telomerase reverse
transcriptase gene (hTERT) showed only low persistence
after systemic delivery.15
In the present study we evaluated the fate of implanted
MSC microtissues in a chronic rat myocardial infarct model.
Microtissues display a more efficient delivery format than
single cell suspensions16 and indicated good retention of
transplanted MSCs. However, the apparently good integra-
tion capacity was associated with a high degree of pro-
grammed cell death. Consequently, we performed in depth
in vitro analyses to further elucidate potential mechanisms
responsible for the fate of implanted MSCs.
Material and Methods
Mouse and rat bone marrow mesenchymal
stem cells (mMSC, rMSC)
MSCs were isolated from transgenic C57Bl/6 mice ex-
pressing enhanced green fluorescent protein (EGFP) under
control of the ubiquitously active beta-actin promoter17 or
from normal Wistar rats using standard protocols.5 Briefly,
bonemarrow cells from femur and tibia were placed on plastic
dishes (Greiner BioOne, Frickenhause, Germany) and the
adherent cell fraction grown in minimum essential medium
(MEM) alpha (Invitrogen, Carlsbad, CA), supplemented with
10% fetal calf serum (FCS; PAA Laboratories, Linz, Austria).
Human bone marrow-derived mesenchymal
stem cells (hMSC)
Bone marrow aspirates were obtained during routine or-
thopedic surgical procedures involving exposure of the iliac
crest, after informed consent (kindly provided by I. Martin).
Marrow aspirates (20ml volumes) were harvested using a
bonemarrowbiopsy needle inserted through the cortical bone;
aspirates were immediately transferred into plastic tubes
containing 15,000 IU heparin.18 The adherent cell fraction was
cultured as described above. All experiments were performed
in accordance to the Swiss Ethic Law, No. StV 21-2006.
Human artery-derived fibroblasts (hAF)
In order to obtain primary human artery-derived fibro-
blasts (hAFs), de-endothelialized vessel segments of human
arteries were minced and cultivated in a 37C humidified 5%
carbon dioxide (CO2)-containing atmosphere and Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA)
supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin solution (Invitrogen). Pure hAFs which had
migrated out of the tissue pieces after 10–14 dayswere serially
passaged and expanded for 4–6 weeks under aforementioned
conditions to desired cell numbers.19
Human cardiac-derived fibroblasts (hCF)
Tissue samples of the right atrial appendage were col-
lected and transferred in cardioplegic solution. After wash-
ing, they were minced and transferred into a 50ml tube and
washed with Joklik’s minimum essential medium (JMEM,
Cell Technologies, Lugano, Switzerland). JMEM was aspi-
rated and the tissue pieces taken up in JMEM supplemented
with 2.5% trypsin (Invitrogen) and transferred into the spin-
ner flask (at 37C). To improve cell survival, oxygen was
supplied by a needle attached to a 0.2 micron filter. The tissue
pieces were digested for 90min and the remaining clumps
separated from the cells by filtering through a polyamide
mesh. Cardiomyocytes and fibroblasts were subsequently
separated by gravitation as adult cardiomyocytes settle faster
than fibroblasts. The supernatant containing mostly cardiac
fibroblasts was plated in DMEM supplemented with 10% FCS
and 1% penicillin/streptomycin.
Cell culture
MSCs, hAFs, and hCFs were cultured in MEM-alpha
supplemented with 10% FCS and 1% penicillium/strepto-
mycin at 37C and 5% CO2 in a humidified incubator. Cell
culture under hypoxic conditions (1% O2) was performed
using a vinyl anaerobic chamber system (Glove Box, Coy
Laboratory Products Inc.).
Characterization of MSCs
Functional differentiation of mouse, rat, and human MSC
as well as hAF into adipocytes and osteoblasts was induced
using standard protocols as described by Pittenger and co-
workers5 (see Fig. 1S).
Flow cytometry analysis (FACS) of hMSC was performed
for further cell characterization (see Fig. 1S). Briefly, cells
were harvested and washed once with cold FACS buffer
(PBS, 2% FCS, 0.5M EDTA, 0.05% sodium azide). The MSCs
were resuspended in FACS buffer and stained either with a
fluorescent- or non-labeled antibody for 20min at 4C in the
dark. The cells stained with the non-labeled antibodies were
washed once with cold FACS buffer and incubated for
20min at 4C in the dark with directly conjugated secondary
antibodies. After additional washing with FACS buffer,
MSCs were resuspended in phosphate-buffered saline (PBS;
Sigma Chemicals, St. Louis, MO) containing 1% parafor-
maldehyde. Flow cytometric analysis was perfomed using a
FACS Calibur (BD). Data were analyzed using FlowJo soft-
ware (Tree Star). Positive gates were defined by exclusion of
99.9% of corresponding isotype controls.
Microtissue formation
Monolayer cultures were trypsinized and single-cell sus-
pensions seeded with indicated cell concentrations into
60-well plates (HLA plate, Greiner-Bio One, Frickenhausen,
Germany). In order to enable gravity-enforced microtissue
formation in hanging drops, the 60-well plateswere incubated
upside down. Microtissues were produced andmaintained in
MEM-alpha medium supplemented with 10% FCS and 1%
penicillin/streptomycin solution.20 Microtissue size was an-
alyzed for at least 10 microtissues per group by bright-field
microscopy with subsequent analysis using image J.
Chronic infarct model
Infarct (n = 10) or sham operations (n = 5) were performed
in 200 g male Wistar rats (8–9 weeks old). Ligation of the left
anterior descending coronary artery was performed in the
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intubated rats during isoflurane (Isoflo ad us. Vet., Abbott
AG, Baar, Switzerland) anesthesia, as described by Pfeffer
and coworkers.21 Briefly, after opening the fourth intercostal
space the heart was exteriorized and the pericardium was
cut. The left anterior descending coronary artery was ligated
between the left atrium and the pulmonary outflow tract
using a 6.0 silk suture (Vicryl & Ethicon, Johnson &
Johnson MEDICAL GmbH, Switzerland). The heart was re-
placed into the thoracic cavity and the chest was immedi-
ately closed. At the end of operation, all animals received
0.02mg/kg subcutaneous buprenorphine (Temgesic, Essex
Chemie AG, Lucerne, Switzerland) for postoperative anal-
gesia (with subsequent doses every 12 h for the first 3 post-
operative days), and 10mg/kg subcutaneous enrofloxacin
(Bayer AG, Leverkusen, Germany) as an antibiotic prophy-
laxis. Animal experiments were performed in accordance to
ethical permission No. 127-2005.
Microtissue implantation
After scar tissue formation for at least 6 weeks, syngeneic
rMSC composed microtissues consisting of 5000 cells per
microtissue were labeled with 10 mM ((5-(and -6)-(((4-chloro-
methyl)benzoyl)amino)tetramethylrhodamine)) (CMTMR)
(Invitrogen) for 30min in 1ml PBS, pH 7.2 in the dark.
The microtissues were washed two times and resuspended
in Hanks’s balanced salt solution (HBSS) buffer for injections.
After opening the fourth intercostal space the heart was ex-
teriorized and approximately 600 microtissues were injected
into the scar area of the infarct using Braun Omnican 50 in-
sulin syringes (U-100, 0.30 · 8mm). The total injection volume
of 50 ml was distributed over multiple injection sites.
Immunohistochemistry and TUNEL
Immunohistochemistry was performed on paraffin sec-
tions of microtissues using the Ventana Benchmark auto-
mated staining system (Ventana Medical Systems, Tuczon,
AZ) and cleaved Caspase-3 primary antibody (Cell Signaling
Technology, Danvers, MA). Primary antibody was detected
with the Ventana iVIEW DAB detection kit, resulting in a
brown reaction product. Sections were counterstained with
hematoxylin and covered with a glass cover slip.
Terminal transferase and biotin-16-dUTP apoptosis
detection (TUNEL) was performed on paraffin sections of
microtissues according to standard protocols. Briefly, de-
paraffinized sections were incubated with 3% H2O2 to block
peroxidase activity. After two washings the specimens were
incubated with TdT reaction buffer (Roche Diagnostics
GmbH, Penzberg, Germany) for 1 h at 37C. The reaction
was stopped, washed, and incubated with Streptavidin-HRP
for 20min at room temperature and further developed with
DAB (Roche Diagnostics GmbH) for 1–2min.
Quantification of immunohistochemical staining
Paraffin sections of microtissues were stained against
cleaved Caspase-3 and images were analyzed using Ax-
iovision Autmess software (Carl Zeiss Microimaging, Ober-
kochen, Germany). The degree of apoptosis was calculated
as a ratio between the area of cleaved Caspase-3 positive cells
(brown staining) and living cells area (blue staining of cy-
toplasm). Statistical analysis was performed using ANOVA
and post hoc Tukey-Kramer test.
Immunofluorescence analysis
For immunofluorescence analysis, explants and micro-
tissues were harvested, washed twice in PBS, fixed for 1 h in
PBS containing 4% paraformaldehyde and subsequently
washed three times for 5min in PBS. Microtissues were
embedded in agarose and prepared for frozen sections. The
frozen specimen (10 mm thick) were washed three times with
PBS and further permeabilized for 10min in PBS containing
0.2% Triton X-100 (Sigma Chemicals). The sections were
sequentially incubated with primary antibodies targeting
Collagen I (polyclonal rabbit, Cedarlane, Burlington, Canada),
Collagen IV (polyclonal rabbit, Cedarlane), Fibronectin
(polyclonal rabbit, Sigma Chemicals,) Laminin (polyclonal,
Sigma Chemicals), sarc. alpha-actinin (monoclonal mouse,
Sigma Chemicals) and cleaved Caspase-3 (polyclonal rabbit,
Cell Signaling Technology, Danvers, MA) for 5 h at room
temperature and the detection antibodies, anti-rabbit Cy2 and
anti-mouse Cy5 ( Jackson Immunochemicals, West Grove, PA)
for an additional 2 h at room temperature. Nuclei were visu-
alized by 4¢,6-diamidin-2-phenylindol (DAPI) (Sigma Chemi-
cals). The specimens were analyzed by confocal laser scanning
microscopy (CLSM; Leica TCS SP5, Leica Microsystems,
Glattbrugg, Switzerland).
Caspase-3/7 activity assay
Caspase-3/7 activity assay was performed according to the
manufactures protocol (Caspase-Glo 3/7 assay, Promega,
Du¨bendorf, Switzerland). Briefly, for Caspase-3/7 activity
10,000 MSCs were seeded to confluence in 96-well plates and
cultured for 2 days or fourmicrotissues, each composed of 2500
MSCs, were grown for 2 days in hanging drops. Caspase-3/7
activity was measured after 2 days in culture with a multiwell
plate reader (Biotek Instruments, Winooski, VT) in a 96-well
plate by luminescence resulting after adding the Caspase-Glo
3/7 buffer in equal amount to the culture medium.
Statistics
Statistical analysis was performed using an unpaired two-
sided student t-test to evaluate significance ( p-value) of the
results.
Results
MSC microtissue formation
In contrast to single cells, injected microtissues are more
adhesive due to their size and an accelerated extracellular
matrix production.16,22 Hence, the aggregation into micro-
tissues prior to injection might improve the retention of mes-
enchymal stem cells in the myocardium. Prior to in vivo
experiments, we have tested microtissue-forming capacity of
rat MSCs by using gravity-induced aggregation. Microtissues
comprising 5000 rMSCs were formedwithin 2 days in hanging
drop cultures. The generated microtissues had a diameter of
about 200mm and come easily through the commonly used
injection needles. The microtissues have demonstrated normal
tissue morphology without any sign of hypoxia. In accordance
with a recent study by Bartosh and coworkers,23 qualitative
immunofluorescence analysis demonstrated the appearance of
extracellularmatrix components such as collagen I, collagen IV,
fibronectin, and laminin after only 2 days in culture, indicative
of their adhesive properties (Fig. 2S).
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rMSC microtissue implantation
To analyze the integration behavior of rMSC-composed
microtissues we used a rat chronic infarct model and injected
the microtissues directly into the scar tissue. Microtissue
implantation was performed in a syngeneic chronic rat
infarct model, at least 6 weeks after ligation of the left
descending coronary artery. Overall, approximately 600
fluorescent-labeled microtissues (5000 cells/microtissue
grown for 2 days) corresponding to 3· 106 cells were injected
into the scar tissue. In previous experiments it could be
demonstrated that myocardial microtissues (composed of
neonatal rat cardiomyocytes) integrated within 7 days into
the myocardium of rats after intrapericardial injection (22).
Therefore we performed a post-transplantation analysis at 2
(n= 5; Fig. 1a–e) and 7 days (n= 5; Fig. 1f–j) after implanta-
tion. HBSS was used as control and analyzed accordingly
after 2 and 7 days. Because no control group showed any
fluorescent signal in the CMTMR-specific wavelength, we
illustrate only the 2-day HBSS control results (Fig. 1k–n). The
scar region was clearly visible in all groups as shown by
thinning of the myocardial wall and reduced number of
cardiomyocytes (Fig. 1o). In the microtissue transplanted
groups, CMTMR positive areas were clearly visible in the
scar tissue after 2 and 7 days (Fig. 1a–j). Already after 2 days,
the spherical shape of the microtissues was no longer obvi-
ous. In addition, after 2 and 7 days, the fluorescent signal
appeared to be not associated with viable MSCs, indicating a
FIG. 1. Appearance of ((5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine)) (CMTMR)-labeled rat bone
marrow stromal cells (rMSC) microtissues implants 2 days (a–e) and 7 days (f–j) after intramyocardial injection into the chronic
scar area. As a control, Hanks’s balanced salt solution (HBSS) was injected into the scar area and analyzed after 2 days (k–n).
Frozen sections were stained for 4¢,6-diamidin-2-phenylindol (DAPI) (blue) and sarcomeric alpha actinin (green); CMTMR is
shown in red. An overview of the infarcted heart is shown by sarcomeric alpha actinin (green) displaying the reduced wall
thickness and cardiomyocyte number in the scar region (o). Color images available online at www.liebertonline.com/tea
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high degree of cell death of the implants (Fig. 1e, j). To better
understand the observations of the transplantation results,
microtissues were systematically analyzed in vitro to inves-
tigate the MSC behavior after tissue formation.
MSCs survival in microtissue format
Although MSC microtissues retain on the injection site,
their survival and persistence might be limited due to cell
death. Therefore, we investigated in more detail whether the
tissue formation process of undifferentiated MSCs itself had
already had an impact on the survival of the cells. Bone
marrow MSCs of mouse, rat, and human origin were re-
aggregated to microtissues with indicated cell numbers and
observed over time. During a 10-days culture period mMSC-
composed microtissues decreased substantially in size and
after 10 days no tissues could be detected, independent of the
initial cell number (Fig. 2). A similar size profile was
FIG. 2. Size profiling of mouse, rat, and human MSC (mMSC, rMSC, hMSC) microtissues. mMSC-composed microtissues
inoculated with 400 and 1000 cells displayed a size reduction of about 40% from day 3 to 7 until after 10 days no tissues could
be detected anymore (data not shown). rMSC-composed microtissues inoculated with 2500 cells and hMSC-composed
microtissues inoculated with 1000 cells displayed an approximately 40% decrease in diameter between 2 and 6 days in cul-
ture. This was confirmed by H&E staining displaying compact microtissues with dying cells. (***p£ 0.001). H&E, hematoxylin
and eosin. Color images available online at www.liebertonline.com/tea
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observed for the rMSC and hMSC microtissues, where a
reduction of about 40% from day 2 to day 6 was measured
(Fig, 2). H&E staining of rat and human MSC-microtissue
confirmed that the cells form a compact tissue after two days
in hanging drop cultures (Fig. 2) with extracellular matrix
expression of collagen I, collagen IV, laminin, and fibronectin
(shown for rat MSC-microtissue; Fig. 2S).
In order to verify that the decrease in tissue mass is related
to cell death rather than tissue disintegration TUNEL anal-
ysis was performed in rat and human MSC microtissues.
TUNEL-positive cells were not observed in monolayer cul-
tures of rMSCs, hMSCs as well as in hAF control cultures
grown for 6 days (Fig. 3a, d, g). After 6 days microtissues
that initially contained 2500 rMSCs displayed a severe loss of
cells and exhibited a high number of TUNEL-positive cells
(Fig. 3c). Similarly, hMSC microtissues displayed a sub-
stantial number of TUNEL-positive cells, which could be
localized throughout the microtissues (Fig. 3f). In control
microtissues composed of artery-derived fibroblasts, TUNEL
positive cells could not be detected, which is in accordance
with earlier results where no severe cell death could be
observed.7
To further determine whether the cells enter apoptosis or
necrosis after tissue formation, we performed quantitative
analysis of Caspase-3/7 activity. The assay was validated by
inducing apoptosis through serum deprivation (0% FCS) and
cultivation under hypoxic conditions (1% atmospheric O2)
with confluent MSC-monolayer cultures (inoculated to con-
fluence with 10,000 cells per well). Both, rMSCs and hMSCs
displayed elevated levels of Caspase-3/7 activity after 24 h
under these conditions (Fig. 4) proving the functionality of
the assay. To compare Caspase activity of rMSCs and hMSCs
in monolayer cultures and microtissue format, 10,000 cells
were seeded to confluency in a 96-well plate. Correspond-
ingly, four microtissues composed of 2500 cells each were
placed into one 96-well plate. Peak levels of Caspase-3/7
activity were observed after 2 days and normalized to the
inoculated cell number. MSCs of both species displayed el-
evated Caspase-3/7 activity after tissue formation (rMSC
582.2 – 83.32 RLU/1000 cells, hMSC 217.00– 12.86 RLU/
1000cells) compared to their monolayer counterparts (rMSC
44.09 – 0.1 RLU/1000 cells, hMSC 54.80– 3.72 RLU/1000
cells) (Fig. 4), clearly proving a strongly enhanced rate of
apoptosis after tissue formation. Human artery fibroblasts as
control cells did not show enhancement of Caspase-3/7 ac-
tivity in microtissues compared to monolayer cultures,
clearly proving that apoptosis is not related to the micro-
tissue culture itself.
MSC microtissue differentiation
Recently it was shown that long-term engrafted MSCs can
undergo osteogenic differentiation in infarctedmouse hearts.12
Therefore, we analyzed the effect of osteogenic differentiation
FIG. 3. Terminal transferase and biotin-16-dUTP apoptosis detection (TUNEL) assay of rMSCs (a–c), hMSC (d–f), and
arterial-derived control fibroblasts (g–i) grown in monolayer and microtissues after 6 days in culture. Note the prominent
amount of TUNEL positive cells (black) in MSC microtissues compared to controls. Color images available online at
www.liebertonline.com/tea
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of MSCs in the microtissue format and its impact on their ap-
optotic activity. MSC microtissues from rat and human origin
were grown in osteogenic differentiation medium (ODM). As
compared to cells cultured in nondifferentiating medium,
rMSCs in ODM displayed an overall lower frequency of cell
death after 6 days, as reflected by a lower number of TUNEL-
positive cells but also by a sustained tissue appearance (Fig. 5a,
b). The cultures of hMSC did not show such a pronounced
effect, as under both culture conditions TUNEL positive cells
could be detected (Fig. 5c, d). However, under osteogenic
conditions a sustained tissue appearance could be observed
after 6 days in culture. Cleaved Caspase-3 immunohisto-
chemistry (IHC) staining was used to further corroborate these
findings. To validate cleaved Caspase-3 IHC rMSCs were
grown in serum depleted medium under hypoxic conditions
and under normal culture conditions. The cultures grown
under starving conditions displayed upregulated cleaved
Caspase-3 in contrast to MSCs cultured under normal condi-
tions (Fig. 6a, b). In the microtissue format, increased levels of
cleaved Caspase-3 were detected in MSC microtissues of rat
and human origin without inducing osteogenic differentiation
(Fig. 6). In contrast, MSC microtissues of both species grown
under osteogenic differentiation conditions markedly attenu-
ated cleaved Caspase-3 levels (Fig. 6). Control microtissues
produced from human fibroblasts isolated from the artery and
the right atrial appendage displayed only low levels of cleaved
Caspase-3 (Fig. 6), clearly proving that apoptosis is a specific
feature of MSCs cultivated in microtissues and not related to
the microtissue culture process per se.
Discussion
Autologous MSCs represent a promising cell source for
cell-based therapies; however, although they are already
used in clinical trials, the current knowledge is limited with
regard to the biological mechanisms involved in their re-
generative and healing capacity.
Single cell implantations of MSCs to treat myocardial de-
fects via systemic or intramyocardial applications have pro-
vided limited therapeutic benefits; this may be also related to
the fact that long term engraftment of these cells within the
heart was found to be rather low.7,24 Thus, efficient inte-
gration, cell survival and persistence appear important for
future implementation of MSCs in cell-based therapies, re-
gardless whether primarily the cells directly and/or their
paracrine action cause their therapeutic effect. The impact of
prolonged MSC survival was demonstrated by Noiseux and
coworkers who implanted Akt overexpressing MSCs, which
resulted in superior improvement of heart functionality.25
MSC-composed microtissues enhance cellular retention and
integration due to their lower motility and higher adhesivity
compared to single cells7,16,22,26 and are therefore an attrac-
tive application format to improve cell-based therapeutic
effects. This is also supported by other studies reporting that
MSCs grown as spheroids in hanging drops displayed in-
creased therapeutic properties such as anti-inflammatory
effects, suggesting that this application format for MSCs is
superior to single cell suspensions.23,27 Nevertheless, sur-
vival and long term engraftment appears to be key for
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FIG. 4. Caspase-3/7 activity
of rMSC, hMSC, and hAF
(human artery-derived fibro-
blast) monolayer and micro-
tissue cultures. To confirm
the assay apoptosis was in-
duced by growing rMSCs
and hMSCs under serum de-
pletion and hypoxia (1% O2
for 24 h). Increased Caspase-
3/7 activity was measured in
both MSC-composed micro-
tissues in comparison to the
monolayer cultures though
the effect was more promi-
nent in the rMSC microtissue
cultures. Control human
artery-derived fibroblasts
displayed no difference in
Caspase 3/7 activity in both
culture formats. (***p< 0.01).
FCS, fetal calf serum.
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achieving optimal therapeutic effects. Detailed analysis of the
cell fate in vitro demonstrated that MSCs form a microtissue
already within 2 days, but soon after formation MSC mi-
crotissues displayed elevated numbers of apoptotic cells. To
exclude that this is not due to the microtissue culture format
we also evaluated other cell types of mesenchymal origin
such as fibroblasts isolated from the artery and the atrial
appendage and did not find increased rates of apoptosis of
these cells compared to adherence cultures. This is fully in
accordance with other microtissue types derived from dif-
ferentiated cells where this effect could not be observed.26
The MSC-specific behavior might be explained by changes
in their microenvironment. In their biological niche they are
embedded in a complex environment composed of marrow
stromal cells, hematopoietic cells, fibroblasts, macrophages,
adipocytes, osteoblasts, osteoclasts, and endothelial cells,28
providing the necessary biological cues for maintained sur-
vival in an undifferentiated state. Once MSCs are either
FIG. 5. TUNEL assay of
rMSC (a, b) and hMSC (c, d)
microtissues without differ-
entiation stimuli and during
osteogenic differentiation af-
ter 6 days in culture. **p< 0.1.
Color images available online
at www.liebertonline.com/
tea
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mobilized and home to the injured sites or are expanded
ex vivo and injected into damaged tissue area, they are
confronted with a ‘‘nonphysiological’’ tissue environment
involving novel cell–cell contacts, extracellular matrix com-
ponents, different cell density, physical properties, growth
factors, and cytokines. Thus, based on our observations, we
hypothesize that in an environment lacking the appropriate
biological cues for maintaining their undifferentiated state
the MSCs have to differentiate for sustained survival or
otherwise undergo apoptosis (Fig. 7). This can be regarded as
a biological safety switch to prevent adverse effects of MSCs
in ectopic organs. This is substantiated by reports demon-
strating that even MSCs transgenic for the pro-survival gene
serin/threonine protein kinase 3 (Akt3), which displayed an
improved survival after 3 and 7 days after intramyocardial
implantation, could hardly be detected after 14 days.25
The lack of specific MSC markers and thus the ability to
evidently monitor only viable MSCs in vivo limits relevant
follow up investigations with regard to long term survival.
Terrovitis and coworkers demonstrated that the survival rate
of iron particle loaded stem cells monitored by magnetic
resonance imaging resulted in an overestimation of cell
survival.29 A low integration and/or survival rate of MSCs
in various tissues was summarized by Karp and Teo, dem-
onstrating an average integration rate of far less than 1% (6).
Thus, almost no adverse effects have been detected following
cellular infusions either intravenously, intraperitoneally, or
intramuscularly, most likely due to the short and not
FIG. 6. Immunohistological
analysis of cleaved Caspase-3
(shown in brown) was con-
firmed by induction of apo-
ptosis of rMSC monolayer
cultures grown under serum
depletion and hypoxia (1%
O2 for 24 h) (a, b). Cleaved
Caspase-3 was increased in
microtissue cultures of rMSC
(c–f) and hMSC (g, h) with-
out differentiation stimuli
after 6 days in culture. In
microtissues cultures harbor-
ing osteogenic differentiation
stimuli cleaved Caspase-3
was clearly reduced. Micro-
tissues composed of control
cardiac and artery-derived
fibroblasts displayed mar-
ginal cleaved Caspase-3
levels. The quantification
analysis of cleaved Caspase-3
stainings shows significant
reduction of the number of
apoptotic cells in the micro-
tissues grown in osteogenic
differentiation media for both
rat and human MSCs.
(***p£ 0.001). Color images
available online at www
.liebertonline.com/tea
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persistent engraftment of undifferentiated MSCs.31 On the
other hand, observations of long term engraftment were as-
sociated with differentiation of MSCs such as osteogenic
differentiation leading to calcifications in the heart12 or the
formation of osteosarcomas.31 At this, the rigid scar tissue
could potentially serve as differentiation stimulus towards
the osteogenic lineage.13,32 Furthermore, predifferentiation
strategies have been shown to improve persistence in bone
tissue after intravenous application of the cells.33
These findings together with earlier investigations may
explain in principle the limited cellular regeneration poten-
tial of current MSC-based clinical trials and may change the
therapeutic strategies away from concepts simply delivering
undifferentiated single cell suspensions. Improved survival
and persistence of MSCs and the retention capacity of mi-
crotissues in combination with predifferentiation strategies
might lead to more efficient MSC-based therapies. However,
further evaluation of MSCs in their native environment and
after integration into injured tissue is required to gain deeper
insight into the biology of MSCs and their role in healing
processes. It is envisaged that a better understanding of the
molecular cues involved in determining the fate of MSCs will
assist us in the development of new strategies to improve the
survival rate of transplanted MSCs and will increase the
overall efficacy of stem cell-based therapies.
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